Fundraising FoxKite Pharma
Santa Monica, US · Founded 2009 · 3 known investors
Find your way into Kite Pharma
Sign up to see every warm intro you have to Kite Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kite Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Founders & leadership
Kite Pharma was founded in 2009 by Arie S. Belldegrun.
AS
MR
Margo R. RobertsExecutive
CB
Cynthia ButittaExecutiveCynthia Butitta is an executive with over 25 years of experience in biotechnology and high technology, spanning roles in both early-stage and Fortune 100 companies. Her background includes mergers and acquisitions, IPO preparation, strategic planning, and operations management.
MB
Marc BetterExecutiveMarc Better is an Executive Officer at Kite Pharma with more than 25 years of experience in cell therapy and biologics development, including upstream and downstream process development, GMP manufacturing, quality oversight, and regulatory interactions across cell therapy and biologics programs.
AB
Arie BelldegrunFounder
Board
JA
Joshua A. KazamBoard director
DB
David BondermanBoard director
FC
RN
SB
Steven B. RuchefskyBoard director
RD
Roy DoumaniBoard director
Investors · 3
Alta Partnerslisted by Alta PartnersJackson · $1M – $12M
How we know: Alta Partners's portfolio page · Not right? Tell us
Funding
SEC filings, press & company announcements$50M disclosed across 1 of 2 rounds · 2014–2025
- Undisclosed amountSeries ASep 2025Source ↗
▶$50MraisedMay 2014 · 15 investors · BiotechnologyRule 506(b)
▶$50MraisedMay 2014 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roy DoumaniDirector
- Joshua A. KazamDirector
- Margo R. RobertsExecutive Officer
- Cynthia ButittaExecutive Officer
- David BondermanDirector
- Jonathan M. PeacockDirector
- Arie S. BelldegrunExecutive Officer, Director
- Marc BetterExecutive Officer
- Farah ChampsiDirector
- Ran NussbaumDirector
- Steven B. RuchefskyDirector
- Rizwana SprouleExecutive Officer
- Keith NolopExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Kite Pharma went on to found or lead other companies.
Frequently asked questions
- What does Kite Pharma do?
- Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
- Who founded Kite Pharma?
- Kite Pharma was founded by Arie S. Belldegrun in 2009.
- Who are Kite Pharma's investors?
- Kite Pharma's investors include Alta Partners, Pontifax Venture Capital, Vida Ventures.
- How much funding has Kite Pharma raised?
- Kite Pharma has disclosed $50M raised across 1 of its 2 known rounds.
- Where is Kite Pharma headquartered?
- Kite Pharma is headquartered in Santa Monica, US.